A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
ConditionPrimary Membranous Nephropathy
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorClimb Bio, Inc.
About this trial
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Eligibility criteria
Qualifiers
Confirmed diagnosis of PMN with positive anti-PLA2R antibodies
CD19+ B cell count ≥40 cells/μL
UPCR ≥2.0 g/g
eGFR ≥35 mL/min/1.73 m²
Disqualifiers
Secondary Membranous Nephropathy
Rapidly progressive glomerulonephritis or other glomerulopathies
Prior B cell-depleting therapy within 24 weeks
Recent use of immunosuppressants
Trial design
Treatments tested in this trial
- budoprutug
Treatment groups
45 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov